natgillin/translations-raw huggingface dataset:
In the RCC study (see section 5.1), diarrhoea was reported in 80.6% of patients in the lenvatinib plus everolimus-treated group (21.0% were Grade ≥ 3) and in 34.0% of patients in the everolimus-treated group (2.0% were Grade ≥ 3). 
V študiji RCC (glejte poglavje 5.1) so poročali o driski pri 80,6 % bolnikov v skupini, zdravljeni z lenvatinibom in everolimusom (21,0 % jih je bilo stopnje ≥ 3), in pri 34,0 % bolnikov v skupini, zdravljeni z everolimusom (2,0 % jih je bilo stopnje ≥ 3).
In patients with severe renal impairment, the recommended starting dose is 10 mg of lenvatinib with 5 mg of everolimus taken once daily. 
Pri bolnikih s hudo okvaro ledvic je priporočeni začetni odmerek 10 mg lenvatiniba in 5 mg everolimusa enkrat na dan. Na podlagi prenašanja posameznega bolnika utegnejo biti potrebne nadaljnje prilagoditve odmerka.
The median time to first onset of was 10.2 weeks (any grade) and 7.6 weeks (Grade ≥ 3) in the lenvatinib plus everolimus-treated group. 
Mediani čas do prvega nastopa v skupini, zdravljeni z lenvatinibom in everolimusom, je bil 10,2 tedna (ne glede na stopnjo) oziroma 7,6 tedna (stopnja ≥ 3).
The median time to onset was 4.9 weeks (any grade) and 6.9 weeks (Grade ≥ 3) in the lenvatinib plus everolimus-treated group. 
Mediani čas do nastopa v skupini, zdravljeni z lenvatinibom in everolimusom, je bil 4,9 tedna (ne glede na stopnjo) oziroma 6,9 tedna (stopnja ≥ 3).
Proteinuria has been reported in patients treated with lenvatinib, usually occurring early in the course of treatment (see section 4.8, Description of selected adverse reactions). 
Pri bolnikih, zdravljenih z lenvatinibom, so poročali o proteinuriji, ki se navadno pojavi kmalu po začetku zdravljenja (glejte poglavje 4.8 Opis izbranih neželenih učinkov).
A yellow body and yellowish-red cap, approximately 14.3 mm in length, marked in black ink with “Є” on the cap, and “LENV 10 mg” on the body. 
Rumeno telo kapsule in rumenkastordeč pokrovček kapsule; kapsula je dolga približno 14,3 mm in ima s črnim črnilom izpisano oznako »Є« na pokrovčku kapsule in »LENV 10 mg« na telesu kapsule.
Gastrointestinal and abdominal painsf 
Infekcijske in parazitske bolezni okužba sečil perinealni absces
• liver damage 
• težave s celjenjem ran,
Adverse reaction Severity 
Raven odmerka
Aspartate aminotransferase increased‡ Hypoalbuminaemia‡ 
Bolezni jeter, žolčnika in žolčevodov zvišana aspartataminotransferaza‡ hipoalbuminemija‡
NAME OF THE MEDICINAL PRODUCT Kisplyx 4 mg hard capsules Kisplyx 10 mg hard capsules 
Kisplyx 4 mg trde kapsule Kisplyx 10 mg trde kapsule
UNIQUE IDENTIFIER - HUMAN READABLE DATA PC: 
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA
NAME OF THE MEDICINAL PRODUCT Kisplyx 10 mg hard capsules lenvatinib 
Kisplyx 10 mg trde kapsule lenvatinib
Renal failure j, †, ‡ Renal impairment‡ Blood creatinine increased Blood urea increased 
zvišan kreatinin v krvi zvišana sečnina v krvi nefrotični sindrom
NAME OF THE MEDICINAL PRODUCT Kisplyx 4 mg hard capsules lenvatinib 
Kisplyx 4 mg trde kapsule lenvatinib
A yellowish-red body and yellowish-red cap, approximately 14.3 mm in length, marked in black ink with “Є” on the cap, and “LENV 4 mg” on the body. 
Rumenkastordeče telo kapsule in rumenkastordeč pokrovček kapsule; kapsula je dolga približno 14,3 mm in ima s črnim črnilom izpisano oznako »Є« na pokrovčku kapsule in »LENV 4 mg« na telesu kapsule.
Constipation Dyspepsia Dry mouth 
• vnetje trebušne slinavke,
With regard to safety, the Agency noted an acceptable safety profile. 
Z vidika varnosti je agencija ugotovila, da je varnostni profil sprejemljiv.
Further information on Praluent can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Praluent. 
Nadaljnje informacije za zdravilo Praluent so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Praluent.
If the desired response is not achieved after 4 to 8 weeks of treatment, the doctor can increase or decrease the dose. 
Če se po štirih do osmih tednih zdravljenja ne doseže želeni odziv, lahko zdravnik odmerek poveča ali zmanjša.
Praluent received a marketing authorisation valid throughout the EU on 23 September 2015. 
Za zdravilo Praluent je bilo 23. septembra 2015 izdano dovoljenje za promet, veljavno po vsej EU.
What measures are being taken to ensure the safe and effective use of Praluent? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Praluent?
Patients or their carers can inject the medicine once they have been trained by a healthcare professional. 
Bolniki ali njihovi negovalci lahko zdravilo injicirajo sami, potem ko jih za to usposobi zdravstveni delavec.
What is Praluent and what is it used for? 
Kaj je zdravilo Praluent in za kaj se uporablja?
Some patients are required to be on a low fat diet. 
Nekateri bolniki morajo biti na dieti z nizko vsebnostjo maščob.
The usual starting dose is 75 mg every two weeks, but patients requiring bigger reductions of blood fat levels may start with 150 mg every two weeks or 300 mg every 4 weeks. 
Običajni začetni odmerek je 75 mg vsaka dva tedna, bolniki, pri katerih je potrebno večje znižanje ravni maščob v krvi, pa lahko začnejo z odmerkom 150 mg vsaka dva tedna ali 300 mg vsake štiri tedne.
The European Medicines Agency decided that Praluent's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Praluent večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
As for all medicines, data on the use of Praluent are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Praluent stalno spremljajo.
Why is Praluent authorised in the EU? 
Zakaj je bilo zdravilo Praluent odobreno v EU?
The most common side effects leading to treatment discontinuation were local injection site reactions. 
Najpogostejši neželeni učinki, zaradi katerih je bilo treba prekiniti zdravljenje, so bile lokalne reakcije na mestu injiciranja.
Other information about Praluent 
Druge informacije o zdravilu Praluent
For more information about using Praluent, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Praluent glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
An overview of Praluent and why it is authorised in the EU 
Pregled zdravila Praluent in zakaj je odobreno v EU
What are the risks associated with Praluent? 
Kakšna tveganja so povezana z zdravilom Praluent?
What benefits of Praluent have been shown in studies? 
Kakšne koristi je zdravilo Praluent izkazalo v študijah?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Praluent have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Praluent upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Praluent is available as a solution for injection in a pre-filled syringe or pre-filled pen (75 and 150 mg). 
Zdravilo Praluent je na voljo kot raztopina za injiciranje v napolnjeni injekcijski brizgi ali napolnjenem injekcijskem peresniku (75 in 150 mg).
Side effects reported with Praluent are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Praluent, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Praluent can also be used without a statin in patients who cannot take statins. 
Zdravilo Praluent se lahko uporablja tudi brez statina pri bolnikih, ki ga ne morejo jemati.
The most common side effects with Praluent (which may affect up to1 in 10 people) are injection site reactions such as pain and redness, problems affecting the nose and throat such as colds, and itching. 
Najpogostejši neželeni učinki zdravila Praluent (ki lahko prizadenejo največ 1 osebo od 10) so reakcije na mestu injiciranja, kot sta bolečina in pordelost, težave, ki prizadenejo nos in grlo, kot so prehladi, in srbenje.
Praluent has been studied in 10 main studies involving over 5,000 adult patients with hypercholesterolaemia (including patients with heterozygous familial disease) and mixed dyslipidaemia. 
Zdravilo Praluent so proučevali v desetih glavnih študijah, v katerih je sodelovalo več kot 5 000 odraslih bolnikov s hiperholesterolemijo (vključno z bolniki s heterozigotno družinsko boleznijo) in mešano dislipidemijo.
In a study involving over 18,000 patients who had established heart disease, less than 10% of patients given Praluent had a cardiovascular event (meaning death, heart attack, stroke, chest pain due to problems with the blood flow to the heart leading to hospitalisation) during the study compared with over 11% of patients given placebo. 
V študiji, v kateri je sodelovalo več kot 18 000 bolnikov s potrjenim srčnim obolenjem, je manj kot 10 % bolnikov, ki so prejemali zdravilo Praluent, imelo srčno-žilni dogodek (tj. smrt, srčni napad, možgansko kap, bolečine v prsnem košu zaradi težav s krvnim pretokom v srce, ki je privedlo do hospitalizacije), v primerjavi z več kot 11 % bolnikov, ki so prejemali placebo.
In patients with atherosclerotic heart disease, Praluent reduced the number of cardiovascular events, in particular heart attacks and strokes. 
Pri bolnikih z aterosklerotičnim srčnim obolenjem je zdravilo Praluent zmanjšalo število srčno-žilnih dogodkov, zlasti srčnih napadov in možganskih kapi.
Before starting treatment with Praluent, other causes of excess cholesterol and abnormal fat levels in the blood should be excluded. 
Pred začetkom zdravljenja z zdravilom Praluent je treba izključiti druge vzroke čezmerne ravni holesterola in nenormalnih ravni maščob v krvi.
Praluent is used in combination with a statin or a statin and other fat-lowering medicines. 
Zdravilo Praluent se uporablja v kombinaciji s statinom ali statinom in drugimi zdravili za zniževanje ravni maščob.
The active substance in Praluent, alirocumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a specific enzyme called PCSK9. 
Učinkovina v zdravilu Praluent, alirokumab, je monoklonsko protitelo (vrsta beljakovine), ki je bilo zasnovano tako, da prepozna encim, imenovan „PCSK9“, in se veže nanj.
It is also used to reduce the risk of heart problems and strokes in patients who have atherosclerotic cardiovascular disease (heart problems such as heart attack, stroke or other problems of the circulatory system caused by fatty deposits build up in the walls of the arteries). 
Uporablja se tudi za zmanjševanje tveganja za težave s srcem in možganske kapi pri bolnikih, ki imajo aterosklerotično srčno-žilno bolezen (težave s srcem, kot so srčni infarkt, možganska kap ali druge težave obtočil, ki jih povzročajo maščobne obloge v stenah arterij).
Praluent is a medicine for lowering levels of fat in the blood. 
Praluent je zdravilo za zniževanje ravni maščob v krvi.
Therefore, Praluent has been approved for use in patients who do not adequately respond to the maximum tolerated dose of statins or who cannot be given statins. 
Zdravilo Praluent je bilo zato odobreno za uporabo pri bolnikih, ki se nezadostno odzovejo na največji odmerek statinov, ki ga še lahko prenašajo, in tistih, ki statinov ne smejo prejemati.
Atherosclerotic heart disease 
Aterosklerotično srčno obolenje
It is used to reduce fat levels in adults with primary hypercholesterolaemia (high levels of blood cholesterol without an identifiable cause, often resulting from the person's genetic makeup) and mixed dyslipidaemia (abnormal levels of different fats in the blood, including cholesterol). 
Uporablja se za zmanjšanje ravni maščobe pri odraslih s primarno hiperholesterolemijo (visokimi ravnmi holesterola v krvi brez določljivega vzroka, ki so pogosto posledica bolnikove genetske zasnove) in mešano dislipidemijo (nenormalnimi ravnmi različnih maščob v krvi, vključno s holesterolom).
The Agency noted that across all studies in patients with primary hypercholesterolaemia and mixed dyslipidaemia, including patients on maximum recommended doses of statins or those intolerant to them, treatment with Praluent led to a significant reduction in LDLcholesterol levels, which is a known risk factor for cardiovascular (affecting the heart and blood vessels) disease. 
Agencija je ugotovila, da so v vseh študijah z zdravilom Praluent pri bolnikih s primarno hiperholesterolemijo in mešano dislipidemijo, vključno pri bolnikih, ki so uporabljali največji priporočeni odmerek statinov, in bolnikih, ki statinov niso prenašali, dokazali pomembno znižanje ravni holesterola LDL, ki je znani dejavnik tveganja za srčno-žilne bolezni (bolezni, ki prizadenejo srce in krvne žile).
How is Praluent used? 
Kako se zdravilo Praluent uporablja?
This helps to reduce the amount of LDL-cholesterol in the blood. 
S tem pripomorejo k zniževanju ravni holesterola LDL v krvi.
The dose of Praluent is adjusted based on the levels of fats in blood and response to the medicine. 
Odmerek zdravila Praluent je treba prilagajati glede na ravni maščob v krvi in odziv na zdravilo.
Some studies looked at Praluent taken on its own, while others studied Praluent in combination with other fat-lowering medicines, including patients on the maximum recommended doses of statins. 
V nekaterih študijah so zdravilo Praluent proučevali kot samostojno zdravilo, v drugih pa v kombinaciji z drugimi zdravili za zniževanje ravni maščob, tudi pri bolnikih, ki so uporabljali največje priporočene odmerke statinov.
Some studies compared Praluent with placebo (a dummy treatment) and others to another medicine for hypercholesterolaemia (ezetimibe). 
V nekaterih študijah so zdravilo Praluent primerjali s placebom (zdravilom brez učinkovine), v drugih pa z drugim zdravilom za hiperholesterolemijo (ezetimibom).
The injection is given under the skin of the abdomen, thigh or upper arm. 
Injekcija se vbrizga pod kožo na trebuhu, stegnu ali nadlahti.
This enzyme attaches to cholesterol receptors on the surface of liver cells and causes these receptors to be absorbed and broken down inside the cells. 
Ta encim se na površini jetrnih celic veže na receptorje holesterola, zaradi česar se receptorji v celicah absorbirajo in razgradijo.
When given on top of standard treatment or on its own, Praluent produced a 24 to 36% greater reduction in blood levels of LDL-cholesterol than ezetimibe. 
Ko so zdravilo Praluent dajali skupaj s standardnim zdravljenjem ali s placebom, so zabeležili za od 24 do 36 % večje znižanje ravni holesterola LDL v krvi kot pri ezetimibu.
These studies showed that when Praluent was given on top of a statin it led to a substantial reduction in blood levels of LDL-cholesterol (between 39 and 62% more than placebo) after 6 months of treatment. 
Študije so pokazale, da je zdravilo Praluent, ki so ga dajali v kombinaciji s statinom, po šestih mesecih zdravljenja znatno znižalo ravni holesterola LDL v krvi (za od 39 do 62 % bolj kot placebo).
These receptors control blood levels of cholesterol, especially LDLcholesterol, by removing it from the bloodstream. 
Receptorji uravnavajo ravni holesterola v krvi, predvsem holesterola LDL, tako da ga odstranijo iz krvnega obtoka.
By attaching and blocking PCSK9, Praluent prevents the receptors from being broken down inside cells and therefore increases the number of these receptors on the cell surface, where they can attach to LDL-cholesterol and remove it from the bloodstream. 
Zdravilo Praluent z vezavo na encim PCSK9 in njegovim zaviranjem preprečuje razgradnjo receptorjev v celicah, kar poveča njihovo število na celični površini, na kateri se lahko vežejo na holesterol LDL ter ga odstranijo iz krvnega obtoka.
It contains the active substance alirocumab. 
Vsebuje učinkovino alirokumab.
How does Praluent work? 
Kako zdravilo Praluent deluje?
Alirocumab also helps to reduce other fatty substances from blood in patients with mixed dyslipidaemia. 
Zdravilo Praluent pri bolnikih z mešano dislipidemijo prav tako pomaga zniževati druge maščobe v krvi.
The European Commission granted a marketing authorisation valid throughout the European Union for Rapiscan on 6 September 2010. 
Evropska komisija je dovoljenje za promet z zdravilom Rapiscan, veljavno po vsej Evropski uniji, izdala 6. septembra 2010.
It is used in adult patients (aged 18 years or over) who are unable to exercise enough for a stress test. 
Uporablja se pri odraslih bolnikih (starejših od 18 let), ki ne morejo dovolj telovaditi za obremenitveni test.
Rapiscan should only be used once within any 24-hour period. 
Zdravilo Rapiscan se lahko uporabi samo enkrat v 24-urnem obdobju.
What measures are being taken to ensure the safe and effective use of Rapiscan? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rapiscan?
This is a summary of the European public assessment report (EPAR) for Rapiscan. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Rapiscan.
The full EPAR for Rapiscan can be found on the Agency's website under EMA website/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) je na voljo na spletni strani agencije EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Rapiscan must only be used in a hospital that has equipment for resuscitation and monitoring the patient. 
Zdravilo Rapiscan se lahko uporablja samo v bolnišnici, ki ima na voljo opremo za oživljanje in spremljanje bolnika.
A risk management plan has been developed to ensure that Rapiscan is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Rapiscan je bil pripravljen načrt obvladovanja tveganj.
The CHMP decided that Rapiscan's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Rapiscan večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The ‘agreement rates' between the first and second scans were similar regardless of which of the two medicines were used for the second scan. 
Stopnje ujemanja med prvim in drugim slikanjem so bile podobne, ne glede na to, katero zdravilo je bilo uporabljeno za drugo slikanje.
Other information about Rapiscan: 
Druge informacije o zdravilu Rapiscan:
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rapiscan. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The patient then undergoes the procedures for radionuclide myocardial perfusion imaging, starting with an injection of a radioactive substance 10 to 20 seconds after the sodium chloride injection. 
Pri bolniku se nato izvede postopek radionuklidnega slikanja miokardne perfuzije, ki se začne z injiciranjem radioaktivne snovi 10 do 20 sekund po injiciranju natrijevega klorida.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rapiscan, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
It is given as a 10-second injection of 400 micrograms into a vein immediately followed by an injection of sodium chloride (salt) solution. 
Daje se kot 10-sekundna 400-mikrogramska injekcija v veno, kateri takoj sledi injiciranje raztopine natrijevega klorida (soli).
The main measure of effectiveness was based on the similarity between the results of the scans with Rapiscan and adenosine. 
Glavno merilo učinkovitosti je temeljilo na podobnosti rezultatov slikanj z zdravilom Rapiscan in adenozinom.
The active substance in Rapiscan, regadenoson, is an A2A adenosine receptor agonist. 
Zdravilna učinkovina v zdravilu Rapiscan, regadenozon, je agonist receptorja adenozina A2A.
What benefit has Rapiscan shown during the studies? 
Kakšne koristi je zdravilo Rapiscan izkazalo med študijami?
They should also stop receiving dipyridamole (a medicine used to prevent blood clots) for at least two days before receiving Rapiscan. 
Prav tako morajo nehati jemati dipiridamol (zdravilo za preprečevanje krvnih strdkov) vsaj dva dni pred prejetjem zdravila Rapiscan.
For more information about treatment with Rapiscan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Rapiscan preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
In two main studies, around 2,000 adult patients first had a myocardial perfusion imaging scan performed using adenosine (another medicine used as a stress agent) followed by a second scan with either adenosine or Rapiscan. 
V dveh glavnih študijah je bilo pri okoli 2 000 odraslih bolnikov slikanje miokardne perfuzije najprej opravljeno z adenozinom (drugim zdravilom, ki se uporablja kot sredstvo za obremenitev), drugo slikanje pa je bilo nato izvedeno z adenozinom ali zdravilom Rapiscan.
Because Rapiscan causes a rapid increase in heart rate and a fall in blood pressure, patients should remain sitting or lying down and be monitored frequently until the effects of the medicine have worn off. 
Ker zdravilo Rapiscan povzroči hitro zvišanje srčnega utripa in znižanje krvnega tlaka, naj bolniki ostanejo v sedečem ali ležečem položaju in pod nadzorom v pogostih časovnih presledkih tako dolgo, dokler učinki zdravila ne izzvenijo.
For further information on the use of Rapiscan, see the summary of product characteristics (also part of the EPAR). 
Za več informacij o uporabi zdravila Rapiscan glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
Rapiscan is used as a ‘stress agent' that has a similar effect on the heart as exercise. 
Zdravilo Rapiscan se uporablja kot „sredstvo za obremenitev“, ki ima podoben učinek na srce kot telesna vadba.
The most common side effects with Rapiscan (seen in more than 1 patient in 10) are headache, dizziness, ST segment changes (an abnormal reading on the electrocardiogram or ECG), flushing (reddening of the skin), dyspnoea (difficulty breathing), gastrointestinal (stomach and gut) discomfort and chest pain. 
Najpogostejši neželeni učinki zdravila Rapiscan (opaženi pri več kot 1 bolniku od 10) so glavobol, omotica, spremembe segmentov ST (nenavaden zapis na elektrokardiogramu ali EKG-ju), zardevanje (pordelost kože), dispneja (oteženo dihanje), prebavne motnje in bolečina v prsih.
It is used in a type of heart scan called ‘radionuclide myocardial perfusion imaging' to see the blood flow in the heart muscle. 
Uporablja se pri vrsti slikanja srca, imenovanega „radionuklidno slikanje miokardne perfuzije“ za opazovanje dotoka krvi v srčno mišico.
The results of scans using Rapiscan and adenosine were comparable. 
Rezultati slikanj z uporabo zdravila Rapiscan in adenozina so bili primerljivi.
Rapiscan must not be used in patients with slow heart rate unless they have a pacemaker, unstable angina (a type of chest pain that changes in severity) that has not been controlled with treatment, severe hypotension (low blood pressure) or decompensated heart failure (when the heart does not work as well as it should). 
Ne smejo ga uporabljati bolniki s počasnim utripom srca, razen če imajo nameščen srčni spodbujevalnik, bolniki z nestabilno angino pektoris (vrsto bolečine v prsih, ki se spreminja v jakosti), ki ni uravnana z zdravili, hudo hipotenzijo (nizkim krvnim tlakom) ali dekompenziranim stanjem srčnega popuščanja (kadar srce ne deluje tako, kot bi moralo).
What is the risk associated with Rapiscan? 
Kakšna tveganja so povezana z zdravilom Rapiscan?